NCT04156256View on ClinicalTrials.gov

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic SyndromesMyeloproliferative NeoplasmChronic Myeloid Leukemia
Interventions
BIOLOGICAL

CD123-CD33 cCAR T cells

CD123-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs.

Trial Locations (2)

Unknown

RECRUITING

Chengdu Military General Hospital, Chengdu

RECRUITING

Peking University Shenzhen Hospital, Shenzhen

Sponsors
All Listed Sponsors
collaborator

Peking University Shenzhen Hospital

OTHER

collaborator

Chengdu Military General Hospital

OTHER

collaborator

iCAR Bio Therapeutics Ltd.

INDUSTRY

lead

iCell Gene Therapeutics

INDUSTRY